0

Close
 
Upcoming Allied Market Research
2023
Herpangina Treatment Market

Herpangina Treatment Market

by Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71), by Symptoms (High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Headache, Neck Pain, Swollen Lymph Glands), by Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Others) and by End User (Hospitals, Homecare, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13398
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Herpangina Treatment Market

Request Now !

Herpangina is a viral infection that causes sores in the mouth. It is a very contagious disease that normally affects small children from 3 to 10 years of age, though adults and teenagers can also get it. Herpangina is caused by a virus and the most common viruses responsible are Echovirus, Coxsackie A16, Enterovirus 71, Coxsackie B. It is spread through saliva, respiratory droplets, stool or directly touching fluid from a sore. Symptoms can differ depending on which virus causes the infection. Herpangina is treated by controlling symptoms. The illness will be varied depending on the severity of the infection, the child’s age, and general health. As herpangina is a viral infection, antibiotics will not benefit.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the herpangina treatment market.

Top Impacting Factors

  • Increase in cases of herpangina viral infection and surge in pediatric populations drive the growth of the herpangina treatment market.
  • In addition, increase in healthcare expenditure; availability of skilled professionals; rise in R&D activities to develop and launch the novel drugs in the market; are some factors, which boost the market growth for herpangina treatment.
  • However, complications such as dehydration, aseptic meningitis, and neurological changes may occur, low birth weight and/or preterm delivery may occur in pregnant women who develop herpangina. Dehydration is another severe problem that may occur in some patients which is projected to hinder the market growth.
  • Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.

Key Benefits of the Report

  • This study presents the analytical depiction of the herpangina treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the herpangina treatment market share.
  • The current market is quantitatively analyzed to highlight the herpangina treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed herpangina treatment market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the herpangina treatment Report

  • Which are the leading players active in the herpangina treatment market?
  • What are the current trends that will influence the herpangina treatment market in the next few years?
  • What are the driving factors, restraints, and opportunities of the herpangina treatment market?
  • What future projections would help in taking further strategic steps?
  • What is "Herpangina treatment"?
  • What is "Herpangina treatment" Market prediction in the future?
  • Who are the leading global players in the "Herpangina treatment" Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Herpangina treatment" Market report?

 Herpangina Treatment Market Report Highlights

Aspects Details
By Virus
  • Coxsackie Virus A
  • Coxsackie Virus B
  • Enterovirus 71
By Symptoms
  • High Fever
  • Sore Throat
  • Blisters Or Ulcers In The Throat & Mouth
  • Difficulty Swallowing
  • Loss Of Appetite
  • Headache
  • Neck Pain
  • Swollen Lymph Glands
By Treatment
  • Topical Anesthetics
  • Ibuprofen or Acetaminophen
  • Others
By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players ViiV Healthcare group of companies, Gilead Sciences, Inc., Mitsubishi Tanabe Pharma Corporation, F. Hoffmann-La Roche Ltd, Vertex Pharmaceuticals Incorporated, AbbVie Inc., Sanofi S.A, GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Novartis AG, Johnson and Johnson Services, Inc.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: HERPANGINA TREATMENT MARKET, BY VIRUS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Virus

    • 4.2. Coxsackie Virus A

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Coxsackie Virus B

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Enterovirus 71

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HERPANGINA TREATMENT MARKET, BY SYMPTOMS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Symptoms

    • 5.2. High Fever

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Sore Throat

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Blisters Or Ulcers In The Throat Mouth

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Difficulty Swallowing

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Loss Of Appetite

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Headache

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Neck Pain

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

    • 5.9. Swollen Lymph Glands

      • 5.9.1. Key Market Trends, Growth Factors and Opportunities

      • 5.9.2. Market Size and Forecast, By Region

      • 5.9.3. Market Share Analysis, By Country

  • CHAPTER 6: HERPANGINA TREATMENT MARKET, BY TREATMENT

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Treatment

    • 6.2. Topical Anesthetics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Ibuprofen Or Acetaminophen

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: HERPANGINA TREATMENT MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Homecare

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Specialty Clinics

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Others

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: HERPANGINA TREATMENT MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Virus

      • 8.2.3. Market Size and Forecast, By Symptoms

      • 8.2.4. Market Size and Forecast, By Treatment

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Herpangina Treatment Market

        • 8.2.7.1. Market Size and Forecast, By Virus
        • 8.2.7.2. Market Size and Forecast, By Symptoms
        • 8.2.7.3. Market Size and Forecast, By Treatment
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Herpangina Treatment Market

        • 8.2.8.1. Market Size and Forecast, By Virus
        • 8.2.8.2. Market Size and Forecast, By Symptoms
        • 8.2.8.3. Market Size and Forecast, By Treatment
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Herpangina Treatment Market

        • 8.2.9.1. Market Size and Forecast, By Virus
        • 8.2.9.2. Market Size and Forecast, By Symptoms
        • 8.2.9.3. Market Size and Forecast, By Treatment
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Virus

      • 8.3.3. Market Size and Forecast, By Symptoms

      • 8.3.4. Market Size and Forecast, By Treatment

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Herpangina Treatment Market

        • 8.3.7.1. Market Size and Forecast, By Virus
        • 8.3.7.2. Market Size and Forecast, By Symptoms
        • 8.3.7.3. Market Size and Forecast, By Treatment
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Herpangina Treatment Market

        • 8.3.8.1. Market Size and Forecast, By Virus
        • 8.3.8.2. Market Size and Forecast, By Symptoms
        • 8.3.8.3. Market Size and Forecast, By Treatment
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Herpangina Treatment Market

        • 8.3.9.1. Market Size and Forecast, By Virus
        • 8.3.9.2. Market Size and Forecast, By Symptoms
        • 8.3.9.3. Market Size and Forecast, By Treatment
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Herpangina Treatment Market

        • 8.3.10.1. Market Size and Forecast, By Virus
        • 8.3.10.2. Market Size and Forecast, By Symptoms
        • 8.3.10.3. Market Size and Forecast, By Treatment
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Herpangina Treatment Market

        • 8.3.11.1. Market Size and Forecast, By Virus
        • 8.3.11.2. Market Size and Forecast, By Symptoms
        • 8.3.11.3. Market Size and Forecast, By Treatment
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Herpangina Treatment Market

        • 8.3.12.1. Market Size and Forecast, By Virus
        • 8.3.12.2. Market Size and Forecast, By Symptoms
        • 8.3.12.3. Market Size and Forecast, By Treatment
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Herpangina Treatment Market

        • 8.3.13.1. Market Size and Forecast, By Virus
        • 8.3.13.2. Market Size and Forecast, By Symptoms
        • 8.3.13.3. Market Size and Forecast, By Treatment
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Virus

      • 8.4.3. Market Size and Forecast, By Symptoms

      • 8.4.4. Market Size and Forecast, By Treatment

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Herpangina Treatment Market

        • 8.4.7.1. Market Size and Forecast, By Virus
        • 8.4.7.2. Market Size and Forecast, By Symptoms
        • 8.4.7.3. Market Size and Forecast, By Treatment
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Herpangina Treatment Market

        • 8.4.8.1. Market Size and Forecast, By Virus
        • 8.4.8.2. Market Size and Forecast, By Symptoms
        • 8.4.8.3. Market Size and Forecast, By Treatment
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Herpangina Treatment Market

        • 8.4.9.1. Market Size and Forecast, By Virus
        • 8.4.9.2. Market Size and Forecast, By Symptoms
        • 8.4.9.3. Market Size and Forecast, By Treatment
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Herpangina Treatment Market

        • 8.4.10.1. Market Size and Forecast, By Virus
        • 8.4.10.2. Market Size and Forecast, By Symptoms
        • 8.4.10.3. Market Size and Forecast, By Treatment
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Herpangina Treatment Market

        • 8.4.11.1. Market Size and Forecast, By Virus
        • 8.4.11.2. Market Size and Forecast, By Symptoms
        • 8.4.11.3. Market Size and Forecast, By Treatment
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Herpangina Treatment Market

        • 8.4.12.1. Market Size and Forecast, By Virus
        • 8.4.12.2. Market Size and Forecast, By Symptoms
        • 8.4.12.3. Market Size and Forecast, By Treatment
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Herpangina Treatment Market

        • 8.4.13.1. Market Size and Forecast, By Virus
        • 8.4.13.2. Market Size and Forecast, By Symptoms
        • 8.4.13.3. Market Size and Forecast, By Treatment
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Herpangina Treatment Market

        • 8.4.14.1. Market Size and Forecast, By Virus
        • 8.4.14.2. Market Size and Forecast, By Symptoms
        • 8.4.14.3. Market Size and Forecast, By Treatment
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Herpangina Treatment Market

        • 8.4.15.1. Market Size and Forecast, By Virus
        • 8.4.15.2. Market Size and Forecast, By Symptoms
        • 8.4.15.3. Market Size and Forecast, By Treatment
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Virus

      • 8.5.3. Market Size and Forecast, By Symptoms

      • 8.5.4. Market Size and Forecast, By Treatment

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Herpangina Treatment Market

        • 8.5.7.1. Market Size and Forecast, By Virus
        • 8.5.7.2. Market Size and Forecast, By Symptoms
        • 8.5.7.3. Market Size and Forecast, By Treatment
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Herpangina Treatment Market

        • 8.5.8.1. Market Size and Forecast, By Virus
        • 8.5.8.2. Market Size and Forecast, By Symptoms
        • 8.5.8.3. Market Size and Forecast, By Treatment
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Herpangina Treatment Market

        • 8.5.9.1. Market Size and Forecast, By Virus
        • 8.5.9.2. Market Size and Forecast, By Symptoms
        • 8.5.9.3. Market Size and Forecast, By Treatment
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Herpangina Treatment Market

        • 8.5.10.1. Market Size and Forecast, By Virus
        • 8.5.10.2. Market Size and Forecast, By Symptoms
        • 8.5.10.3. Market Size and Forecast, By Treatment
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Herpangina Treatment Market

        • 8.5.11.1. Market Size and Forecast, By Virus
        • 8.5.11.2. Market Size and Forecast, By Symptoms
        • 8.5.11.3. Market Size and Forecast, By Treatment
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Herpangina Treatment Market

        • 8.5.12.1. Market Size and Forecast, By Virus
        • 8.5.12.2. Market Size and Forecast, By Symptoms
        • 8.5.12.3. Market Size and Forecast, By Treatment
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. F. Hoffmann-La Roche Ltd

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Gilead Sciences, Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. GlaxoSmithKline Plc

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Johnson And Johnson Services, Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Merck And Co., Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Pfizer Inc.

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. AbbVie Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Vertex Pharmaceuticals Incorporated

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. ViiV Healthcare Group Of Companies

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Sanofi S.A

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Novartis AG

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Mitsubishi Tanabe Pharma Corporation

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HERPANGINA TREATMENT MARKET, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL HERPANGINA TREATMENT MARKET FOR COXSACKIE VIRUS A, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL HERPANGINA TREATMENT MARKET FOR COXSACKIE VIRUS B, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL HERPANGINA TREATMENT MARKET FOR ENTEROVIRUS 71, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL HERPANGINA TREATMENT MARKET, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL HERPANGINA TREATMENT MARKET FOR HIGH FEVER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL HERPANGINA TREATMENT MARKET FOR SORE THROAT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL HERPANGINA TREATMENT MARKET FOR BLISTERS OR ULCERS IN THE THROAT MOUTH, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL HERPANGINA TREATMENT MARKET FOR DIFFICULTY SWALLOWING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL HERPANGINA TREATMENT MARKET FOR LOSS OF APPETITE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL HERPANGINA TREATMENT MARKET FOR HEADACHE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL HERPANGINA TREATMENT MARKET FOR NECK PAIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL HERPANGINA TREATMENT MARKET FOR SWOLLEN LYMPH GLANDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL HERPANGINA TREATMENT MARKET, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL HERPANGINA TREATMENT MARKET FOR TOPICAL ANESTHETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL HERPANGINA TREATMENT MARKET FOR IBUPROFEN OR ACETAMINOPHEN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL HERPANGINA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL HERPANGINA TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL HERPANGINA TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL HERPANGINA TREATMENT MARKET FOR HOMECARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL HERPANGINA TREATMENT MARKET FOR SPECIALTY CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL HERPANGINA TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. GLOBAL HERPANGINA TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA HERPANGINA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. U.S. HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 30. U.S. HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 31. U.S. HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 32. U.S. HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. CANADA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 34. CANADA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 35. CANADA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 36. CANADA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 37. MEXICO HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 38. MEXICO HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 39. MEXICO HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE HERPANGINA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 42. EUROPE HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 43. EUROPE HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. FRANCE HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 47. FRANCE HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 48. FRANCE HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 49. FRANCE HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. GERMANY HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 51. GERMANY HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 52. GERMANY HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 53. GERMANY HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. ITALY HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 55. ITALY HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 56. ITALY HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 57. ITALY HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. SPAIN HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 59. SPAIN HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 60. SPAIN HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 61. SPAIN HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 62. UK HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 63. UK HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 64. UK HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 65. UK HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 66. RUSSIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 67. RUSSIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 68. RUSSIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 69. RUSSIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. REST OF EUROPE HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 71. REST OF EUROPE HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 72. REST OF EUROPE HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 73. REST OF EUROPE HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC HERPANGINA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 75. ASIA-PACIFIC HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 76. ASIA-PACIFIC HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 77. ASIA-PACIFIC HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 78. ASIA-PACIFIC HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. CHINA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 80. CHINA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 81. CHINA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 82. CHINA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. JAPAN HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 84. JAPAN HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 85. JAPAN HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 86. JAPAN HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 87. INDIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 88. INDIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 89. INDIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 90. INDIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH KOREA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH KOREA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH KOREA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH KOREA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. AUSTRALIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 96. AUSTRALIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 97. AUSTRALIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 98. AUSTRALIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. THAILAND HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 100. THAILAND HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 101. THAILAND HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 102. THAILAND HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 103. MALAYSIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 104. MALAYSIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 105. MALAYSIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 106. MALAYSIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. INDONESIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 108. INDONESIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 109. INDONESIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 110. INDONESIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 113. REST OF ASIA PACIFIC HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 114. REST OF ASIA PACIFIC HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA HERPANGINA TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 116. LAMEA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 117. LAMEA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 118. LAMEA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 119. LAMEA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 120. BRAZIL HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 121. BRAZIL HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 122. BRAZIL HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 123. BRAZIL HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 124. SOUTH AFRICA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 125. SOUTH AFRICA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 126. SOUTH AFRICA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 127. SOUTH AFRICA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 128. SAUDI ARABIA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 129. SAUDI ARABIA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 130. SAUDI ARABIA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 131. SAUDI ARABIA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 132. UAE HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 133. UAE HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 134. UAE HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 135. UAE HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. ARGENTINA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 137. ARGENTINA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 138. ARGENTINA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 139. ARGENTINA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 140. REST OF LAMEA HERPANGINA TREATMENT, BY VIRUS, 2022-2032 ($MILLION)
  • TABLE 141. REST OF LAMEA HERPANGINA TREATMENT, BY SYMPTOMS, 2022-2032 ($MILLION)
  • TABLE 142. REST OF LAMEA HERPANGINA TREATMENT, BY TREATMENT, 2022-2032 ($MILLION)
  • TABLE 143. REST OF LAMEA HERPANGINA TREATMENT, BY END USER, 2022-2032 ($MILLION)
  • TABLE 144. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 145. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 146. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 147. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 148. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 150. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 151. GILEAD SCIENCES, INC.: OPERATING SEGMENTS
  • TABLE 152. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 153. GILEAD SCIENCES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 155. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 156. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 157. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 158. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
  • TABLE 160. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 161. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 162. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 163. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 164. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 165. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 166. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 167. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 168. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 169. PFIZER INC.: KEY EXECUTIVES
  • TABLE 170. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 171. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 172. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 173. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 175. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 176. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 177. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 178. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. VERTEX PHARMACEUTICALS INCORPORATED: KEY EXECUTIVES
  • TABLE 180. VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT
  • TABLE 181. VERTEX PHARMACEUTICALS INCORPORATED: OPERATING SEGMENTS
  • TABLE 182. VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 183. VERTEX PHARMACEUTICALS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. VIIV HEALTHCARE GROUP OF COMPANIES: KEY EXECUTIVES
  • TABLE 185. VIIV HEALTHCARE GROUP OF COMPANIES: COMPANY SNAPSHOT
  • TABLE 186. VIIV HEALTHCARE GROUP OF COMPANIES: OPERATING SEGMENTS
  • TABLE 187. VIIV HEALTHCARE GROUP OF COMPANIES: PRODUCT PORTFOLIO
  • TABLE 188. VIIV HEALTHCARE GROUP OF COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. SANOFI S.A: KEY EXECUTIVES
  • TABLE 190. SANOFI S.A: COMPANY SNAPSHOT
  • TABLE 191. SANOFI S.A: OPERATING SEGMENTS
  • TABLE 192. SANOFI S.A: PRODUCT PORTFOLIO
  • TABLE 193. SANOFI S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 194. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 195. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 196. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 197. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 198. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 199. MITSUBISHI TANABE PHARMA CORPORATION: KEY EXECUTIVES
  • TABLE 200. MITSUBISHI TANABE PHARMA CORPORATION: COMPANY SNAPSHOT
  • TABLE 201. MITSUBISHI TANABE PHARMA CORPORATION: OPERATING SEGMENTS
  • TABLE 202. MITSUBISHI TANABE PHARMA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 203. MITSUBISHI TANABE PHARMA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HERPANGINA TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HERPANGINA TREATMENT MARKET
  • FIGURE 3. SEGMENTATION HERPANGINA TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HERPANGINA TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHERPANGINA TREATMENT MARKET
  • FIGURE 11. HERPANGINA TREATMENT MARKET SEGMENTATION, BY BY VIRUS
  • FIGURE 12. HERPANGINA TREATMENT MARKET FOR COXSACKIE VIRUS A, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. HERPANGINA TREATMENT MARKET FOR COXSACKIE VIRUS B, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. HERPANGINA TREATMENT MARKET FOR ENTEROVIRUS 71, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. HERPANGINA TREATMENT MARKET SEGMENTATION, BY BY SYMPTOMS
  • FIGURE 16. HERPANGINA TREATMENT MARKET FOR HIGH FEVER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. HERPANGINA TREATMENT MARKET FOR SORE THROAT, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. HERPANGINA TREATMENT MARKET FOR BLISTERS OR ULCERS IN THE THROAT MOUTH, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. HERPANGINA TREATMENT MARKET FOR DIFFICULTY SWALLOWING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. HERPANGINA TREATMENT MARKET FOR LOSS OF APPETITE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. HERPANGINA TREATMENT MARKET FOR HEADACHE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. HERPANGINA TREATMENT MARKET FOR NECK PAIN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. HERPANGINA TREATMENT MARKET FOR SWOLLEN LYMPH GLANDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. HERPANGINA TREATMENT MARKET SEGMENTATION, BY BY TREATMENT
  • FIGURE 25. HERPANGINA TREATMENT MARKET FOR TOPICAL ANESTHETICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. HERPANGINA TREATMENT MARKET FOR IBUPROFEN OR ACETAMINOPHEN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. HERPANGINA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. HERPANGINA TREATMENT MARKET SEGMENTATION, BY BY END USER
  • FIGURE 29. HERPANGINA TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. HERPANGINA TREATMENT MARKET FOR HOMECARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. HERPANGINA TREATMENT MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. HERPANGINA TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 33. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 34. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 35. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 36. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 37. COMPETITIVE DASHBOARD
  • FIGURE 38. COMPETITIVE HEATMAP: HERPANGINA TREATMENT MARKET
  • FIGURE 39. Top player positioning, 2022
  • FIGURE 40. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. GILEAD SCIENCES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. GILEAD SCIENCES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. GILEAD SCIENCES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. VERTEX PHARMACEUTICALS INCORPORATED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. VERTEX PHARMACEUTICALS INCORPORATED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. VERTEX PHARMACEUTICALS INCORPORATED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. VIIV HEALTHCARE GROUP OF COMPANIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. VIIV HEALTHCARE GROUP OF COMPANIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. VIIV HEALTHCARE GROUP OF COMPANIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. SANOFI S.A: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. SANOFI S.A: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. SANOFI S.A: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 70. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 72. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 73. MITSUBISHI TANABE PHARMA CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 74. MITSUBISHI TANABE PHARMA CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 75. MITSUBISHI TANABE PHARMA CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Herpangina Treatment Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers